Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01973049 · ClinicalTrials.gov registry record · Phase 3
UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 202
- Enrollment target
NCT01973049 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 202 participants.
The verdict
NCT01973049, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 202 participants
- Enrollment target
Study Summary
To demonstrate the effectiveness of DCV 3DAA fixed dose combination with or without Ribavirin in treatment naive cirrhotic subjects.
Interventions
- DRUG Ribavirin
- DRUG Daclatasvir
- DRUG BMS-791325
- DRUG Asunaprevir
- DRUG Placebo matching Ribavirin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 202 participants |
| Start Date | 2013-12 |
| Est. Completion | 2014-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01973049
The ClinicalTrials.gov registry entry for NCT01973049 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 202 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Ribavirin is the first listed.
NCT01973049 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01973049 about?
NCT01973049 is a clinical study titled "UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis". To demonstrate the effectiveness of DCV 3DAA fixed dose combination with or without Ribavirin in treatment naive cirrhotic subjects.
What is the current status of trial NCT01973049?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 202 participants. The study started on 2013-12. Estimated completion is 2014-11.
What interventions are being tested in trial NCT01973049?
The interventions under investigation include: Ribavirin (DRUG), Daclatasvir (DRUG), BMS-791325 (DRUG), Asunaprevir (DRUG), Placebo matching Ribavirin (DRUG).
Who is sponsoring clinical trial NCT01973049?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.